Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has reported positive Phase 2 trial results for ATH434, its lead candidate for Multiple System Atrophy (MSA), a rare and progressive Parkinsonian disorder with no approved treatments. The study demonstrated up to 48% slowing of disease progression on a key clinical endpoint and showed a favourable safety profile. The drug, which works by reducing excess iron in the brain, also exhibited trends in lowering brain atrophy. With Orphan Drug Designation in the US and EU, strong intellectual property, and a recent $40 million capital raise, Alterity is accelerating regulatory discussions and preparing for further data presentations in 2025 as it advances ATH434 toward potential approval.
